Microbix Biosystems Inc. faced a notable decline in its stock price, closing down 3.13% on the TSX.
Microbix Biosystems Inc. (MBX.TO) saw its stock price drop to CA$0.31 in the latest trading session, reflecting a 3.13% decrease. This downturn raises questions about the company's current performance and market sentiment.
Investor takeaway: Investors should be cautious as Microbix continues to grapple with a negative profit margin and a lack of recent positive news to bolster confidence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$44.00M
52W high
$0.34
52W low
$0.21
1W change
+6.67%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 25.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+25.0% Upside
Current Price
C$0.32
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
44.3%
Annualized
90-Day Vol
55.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.29 – C$0.40 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.38 | C$0.29 – C$0.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Microbix's market cap now sits at CA$44 million.
With a market cap of CA$44 million and a profit margin of -38.62%, Microbix is under pressure to demonstrate financial viability.
Bull case
If Microbix can effectively use its recent advancements in test-ingredient manufacturing and grow its market share, there could be potential for a long-term recovery.
Bear case
The ongoing losses and lack of profitability, along with today’s stock decline, suggest deeper issues that may hinder future growth and investor confidence.
Market Reaction
The 3.13% drop in Microbix's stock price reflects a broader investor sentiment that is cautious about the company's financial health. With a market cap of CA$44 million and no dividend yield, investors are likely weighing the risks of holding onto this stock amidst ongoing losses.
Profitability Concerns
Microbix's profit margin currently stands at -38.62%, indicating significant challenges in turning revenue into profit. This financial strain could deter potential investors and contribute to the stock's decline, especially in a market that favors profitability.
Looking Ahead
As Microbix prepares for its upcoming Q2 fiscal 2026 results on May 14, 2026, stakeholders will be keenly watching for signs of improvement. The company's ability to turn around its financial performance will be crucial in regaining investor confidence.
Advertisement
